title: A Remarkable Medicine Has Been Overlooked: Including an Autobiography and the Clinical Section of the Broad Range of Use of Phenytoin
author:  Jack Dreyfus 
description: Many people live one life. Jack Dreyfus has had two. The first was when he founded the Dreyfus Fund. He became known as "the most singular and effective personality to appear on Wall Street since the days of Joseph Kennedy and Bernard Baruch" ("Life" magazine). The author's second life began in 1963 when, in the midst of a severe depression, he asked his physician to let him try a medicine usually prescribed for epilepsy. The medicine (phenytoin) brought him back to good health almost overnight. When he saw six other people have similar results, he realized he had an obligation to investigate further. He retired from his two highly successful businesses, established a charitable medical foundation, and spent the last 30 years of his life and $80 million obtaining information about the many uses of phenytoin. He found that it had been reported useful in the medical literature for over 70 symptoms and disorders. This information, in 20 different languages, has been translated and condensed into three bibliographies and sent to all the physicians in the United States. In spite of this, phenytoin is still being overlooked because of a flaw in the US system of bringing medicines to the public. Dreyfus's attempts to correct this tragic misunderstanding have led to the highest levels of government - but he has found government too busy with problems to have time for solutions.
zlib_text: PHENYTOIN
  CAS No. 57-41-0 
  First Listed in the First Annual Report on Carcinogens 
  NH
  HN
  O
  O
  CARCINOGENICITY
  Phenytoin is reasonably anticipated to be a human carcinogen based on sufficient
  evidence in experimental animals. An IARC Working Group reported that there is inadequate
  evidence for the carcinogenicity of phenytoin in humans (IARC 1996). 
  Cancer, mostly
  neuroblastoma and tumors of neural crest origin, has been reported in six children aged 3 years
  or less who had been diagnosed as having congenital abnormalities thought to be induced by
  prenatal exposure to phenytoin. Although the number of patients is small, the concordance of 
  rare events suggests that phenytoin may be a transplacental carcinogen in humans. There is also
  one report of malignant mesenchymoma in a patient with phenytoin malformations (IARC
  1982). There have been several case reports of lymphomas among individuals under phenytoin
  therapy. However, no significant excess of lymphoma was reported in two follow-up 